A randomized, double blind, placebo controlled, parallel group, study investigating the safety and efficacy over 12 weeks treatment period of MAP0010 [budesonide] in asthmatic infants and children 12 months to 8 years of age

Trial Profile

A randomized, double blind, placebo controlled, parallel group, study investigating the safety and efficacy over 12 weeks treatment period of MAP0010 [budesonide] in asthmatic infants and children 12 months to 8 years of age

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Aug 2016

At a glance

  • Drugs Budesonide (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms CASTLE-I
  • Sponsors MAP Pharmaceuticals
  • Most Recent Events

    • 23 Feb 2009 Co-primary endpoint 'Daytime symptom score' has not been met.
    • 23 Feb 2009 Co-primary endpoint 'Night time symptom score' has not been met.
    • 26 Jan 2009 Status changed from active, no longer recruiting to completed, as reported on ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top